Michael A Norcross

US Patent:

20030229203, Dec 11, 2003

Filed:

Mar 18, 2003

Appl. No.:

10/392355

Inventors:

Tamas Oravecz - Palo Alto CA, US
Michael Norcross - Bethesda MD, US

International Classification:

C07K014/715
C07H021/04
C12P021/02
C12N005/06

US Classification:

530/350000, 536/023500, 435/069100, 435/320100, 435/325000

Abstract:

The present invention provides the nucleotide and amino acid sequence of truncated RANTES (3-68), which has the same amino acid sequence as the wild-type RANTES, but with a Serine/Proline truncation at positions 1 and 2 from the N-terminus, respectively. CD26 is a leukocyte activation marker that possesses dipeptidyl peptidase IV (DPPIV) activity but whose natural substrates and immunological functions had not been previously defined. Several chemokines, including RANTES (regulated on activation, normal T expressed and secreted) are provided, which are substrates for human CD26. The truncated RANTES (3-68) lacked the ability of native RANTES (1-68) to increase the cytosolic calcium concentration in human monocytes, but it still induces this response in macrophages activated with macrophage colony-stimulating factor (M-CSF). RANTES (3-68) retains the ability to stimulate CCR5 receptors and to inhibit the cytopathic effects of HIV-1. The invention provides methods for identifying compounds that affect DPPIV-medicated chemokine cleavage, methods for inhibiting HIV infection and treating individuals having or at risk of having HIV infection, methods for diagnosis and/or prognosis of individuals having a chemokine-associated disorder and methods for accelerating wound healing and angiogenesis, all based on the discovery of DPPIV-mediated cleavage of chemokines.

US Patent:

20090214569, Aug 27, 2009

Filed:

Aug 25, 2006

Appl. No.:

11/990953

Inventors:

Jinhai Wang - Gaithersburg MD, US
Michael Norcross - Bethesda MD, US

Assignee:

Government of the US, as represented by the Secretary, Dept. of Health & Human Services - Rockville MD

International Classification:

A61K 39/21
C07K 16/18
C12N 5/00

US Classification:

4241601, 5303879, 435325, 4242081

Abstract:

The instant invention provides antibodies, vaccines, and immunogenic compositions, for the treatment and prevention of HIV infection. The invention further provides kits comprising the antibodies, vaccines and immunogenic compositions, of the invention.

US Patent:

6534626, Mar 18, 2003

Filed:

Sep 14, 2000

Appl. No.:

09/555663

Inventors:

Tamas Oravecz - Palo Alto CA
Michael A. Norcross - Bethesda MD

Assignee:

The United States of America as represented by the Department of Health Human Services - Washington DC

International Classification:

C07K 500

US Classification:

530300, 500324, 4353201, 435 911, 536 231, 536 2433

Abstract:

The present invention provide the nucleotide and amino acid sequence of truncated RANTES (3-68) which has the same amino acid sequence as the wild-type RANTES, but with a serine/proline truncation at positions 1 and 2 from the N-terminus, respectively.